United Therapeutics Corporation UTHR
Set alert
596.13 USD -2.59 -0.43%
At close · Nov 2
596.13 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
592.47 Day range 600.90
430.02 52-week range 609.99
- YTD
- +22.35%
- 1 year
- +33.83%
- Open
- 596.54
- Prev close
- 598.72
- Mkt cap
- 25.57B
- Vol
- 419.87K
- Avg vol
- 716.02K
- EPS
- 27.92
- P/E
- 21.35
- Div yield
- 0.00%
More statistics
- Low
- 592.47
- High
- 600.90
- Forward P/E
- 17.59
- Beta
- 0.48
- Short ratio
- 2.42
- Inst. own
- 100.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 527.10
- 200-d avg
- 531.54
- 1y target
- 670.93
Analyst view
Consensus: buy
Buy
Price target (mean) 670.93 +12.5% upside
Now 596.13
- Target (low)
- 368.00
- Target (mean)
- 670.93
- Target (high)
- 850.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 6.04 | 4.40 – 7.26 | 7.16 | -15.6% | 781.14M | -2.3% | 14 |
| Next quarter | 7.43 | 3.05 – 10.15 | 7.70 | -3.5% | 833.64M | +5.5% | 14 |
| Current year | 26.63 | 22.65 – 30.81 | 27.86 | -4.4% | 3.18B | -0.1% | 14 |
| Next year | 31.14 | 21.87 – 38.08 | 26.63 | +17.0% | 3.60B | +13.4% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 19, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | BTIG | Upgrade | Neutral | Buy |
| Sep 24, 2026 | Goldman Sachs | Initiated | — | Sell |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 23, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 10, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Apr 10, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Mar 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Mar 23, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 12, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 5, 2026 | UBS | Maintained | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Feb 26, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 26, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 26, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 6, 2026 | UBS | Maintained | Buy | Buy |
| Nov 6, 2025 | UBS | Maintained | Buy | Buy |
| Oct 30, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 30, 2025 | RBC Capital | Maintained | Outperform | Outperform |